Gabelli Funds LLC Sells 23,174 Shares of Stryker Corporation $SYK

Gabelli Funds LLC trimmed its position in Stryker Corporation (NYSE:SYKFree Report) by 22.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 81,215 shares of the medical technology company’s stock after selling 23,174 shares during the period. Gabelli Funds LLC’s holdings in Stryker were worth $28,545,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of the company. VanderPol Investments L.L.C. raised its stake in shares of Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after purchasing an additional 28 shares in the last quarter. Lantz Financial LLC raised its stake in shares of Stryker by 5.0% in the third quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock valued at $225,000 after purchasing an additional 29 shares in the last quarter. Stonebridge Capital Advisors LLC raised its stake in shares of Stryker by 0.4% in the third quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock valued at $2,661,000 after purchasing an additional 29 shares in the last quarter. Tcfg Wealth Management LLC raised its stake in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock valued at $403,000 after purchasing an additional 29 shares in the last quarter. Finally, Mechanics Financial Corp raised its stake in shares of Stryker by 1.2% in the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after purchasing an additional 30 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president directly owned 13,137 shares in the company, valued at approximately $3,728,937.45. This trade represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. 4.60% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of brokerages recently commented on SYK. The Goldman Sachs Group restated a “neutral” rating and issued a $361.00 target price on shares of Stryker in a research note on Friday, May 1st. Evercore set a $355.00 target price on Stryker in a research note on Friday, May 1st. Canaccord Genuity Group cut their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 target price on Stryker in a research note on Friday, May 1st. Finally, BTIG Research dropped their price objective on Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $395.48.

Get Our Latest Stock Analysis on Stryker

Stryker Stock Performance

Stryker stock opened at $312.99 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The stock has a fifty day moving average price of $328.54 and a two-hundred day moving average price of $351.06. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The firm has a market capitalization of $119.99 billion, a P/E ratio of 36.23, a P/E/G ratio of 1.93 and a beta of 0.80.

Stryker (NYSE:SYKGet Free Report) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The company had revenue of $6.02 billion for the quarter, compared to analyst estimates of $6.34 billion. During the same quarter in the prior year, the company earned $2.84 earnings per share. The business’s revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, analysts anticipate that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.

Featured Articles

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Corporation (NYSE:SYKFree Report).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.